Can roziglitazone prescribed for the treatment of ovarian cancer?
Best insight from top research papers
Rosiglitazone, a peroxisome proliferator-activated receptor-γ (PPARγ) agonist, shows promise in ovarian cancer treatment. Studies indicate that rosiglitazone, in combination with olaparib, can synergistically inhibit ovarian cancer growth by ameliorating senescence and enhancing anti-tumor effects . Additionally, rosiglitazone has been found to reverse multidrug resistance in ovarian cancer cells by downregulating the Wnt/β-catenin pathway, thereby reducing P-glycoprotein expression . Furthermore, PPARγ ligands like rosiglitazone have been studied for their potential as cancer therapeutic agents, affecting ovarian cancer cell proliferation and PPARγ expression . Another study highlights that ciglitazone, a PPARγ ligand similar to rosiglitazone, inhibits glucose uptake in ovarian cancer cells, leading to increased apoptosis and decreased tumor mass . Therefore, rosiglitazone, through its PPARγ activation, demonstrates potential in managing ovarian cancer by influencing cell cycle, apoptosis, and tumor growth .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
| Roziglitazone, a thiazolidinedione, did not inhibit ovarian cancer cell proliferation in a PPARγ independent manner. Therefore, it may not be effective for treating ovarian cancer based on this study. | |
33 Citations | Roziglitazone shows potential for treating ovarian cancer by suppressing multidrug resistance through downregulation of FZD1 and MDR1 genes, indicating a promising therapeutic approach. |
10 Citations | Rosiglitazone, in combination with olaparib, shows potential for managing ovarian cancer by reducing senescence and enhancing anti-tumor effects, as demonstrated in the study. |
Open access•Journal Article 1 Citations | Rosiglitazone inhibits SKOV3 ovarian cancer cell proliferation and induces apoptosis by activating PPARgamma and downregulating c-myc, suggesting potential therapeutic benefits in ovarian cancer treatment. |
1 Citations | Not addressed in the paper. |
Related Questions
What is the effect of SIRT1 inhibitors on cell proliferation in ovarian cancer?5 answersSIRT1 inhibitors have been shown to have an effect on cell proliferation in ovarian cancer. MHY2245, a synthetic SIRT inhibitor, exhibited potent cytotoxicity against SKOV3 cells and significantly inhibited SIRT1 enzyme activity. Another SIRT1 inhibitor, EX-527, was found to reduce primordial follicle activation and growth induced by cyclophosphamide (CPM). MiR-142-3p, a microRNA, inhibited the proliferation and chemoresistance of ovarian cancer cells by targeting SIRT1. Additionally, miR-506-3p was found to inhibit proliferation and promote apoptosis of ovarian cancer cells by inactivating the SIRT1/AKT/FOXO3a signaling pathway. On the other hand, cytoplasmic localization of SIRT1 was found to suppress the mesenchymal program, activate the epithelial program, and inhibit migration and invasion of ovarian carcinoma cells. These findings suggest that SIRT1 inhibitors have the potential to inhibit cell proliferation and promote apoptosis in ovarian cancer cells.
Introduction of ovarian cancer?5 answersOvarian cancer is a leading cause of premature mortality worldwide. It is often diagnosed at an advanced stage, leading to poor outcomes in the metastatic phase. Surgery is a key intervention for both curative and palliative treatment, providing significant benefits to survival outcomes. In addition to surgery, patients with ovarian cancer benefit from various pharmacological treatments, including chemotherapy and targeted agents. Advances in treatment have been made through a better understanding of the biology and pathogenetic mechanisms of tumorigenesis. For example, the discovery of homologous recombination deficiency, particularly BRCA gene mutations, has led to the implementation of PARP inhibitors as maintenance therapy in platinum-sensitive ovarian cancer. Antiangiogenic agents and immunotherapy have also been explored, although more research is needed to refine patient selection. Despite these advancements, the prognosis for patients with advanced disease or treatment resistance remains poor. Personalized treatment approaches and the development of new drugs are needed to improve outcomes in ovarian cancer.
How insulin signalling pathway is involved in ovarian cancer?4 answersInsulin signaling pathway is involved in ovarian cancer through the interplay between insulin, insulin-like growth factors (IGFs), insulin-like growth factor binding proteins (IGFBPs), and insulin-like growth factor receptor 1 (IGF1R). The activation of AKT, a downstream target of the IGF signaling pathway, is associated with taxol resistance in ovarian cancer cells. IGF2, a member of the IGF family, plays a role in modulating taxol resistance and its high expression in ovarian tumors is associated with advanced stage, tumor grade, and reduced disease-free survival. Inhibition of the IGF pathway can restore sensitivity to taxol in drug-resistant ovarian carcinoma cells. The expression levels of key proteins involved in the insulin-like growth factor signaling pathway, including IGF1, IGF1R, and AKT, are significantly higher in cisplatin-resistant ovarian cancer cells. These findings suggest that targeting the insulin signaling pathway, particularly IGF2, may be a potential therapeutic strategy for ovarian cancer.
What is the medicinal treatment of ovarian cancer?4 answersThe medicinal treatment of ovarian cancer includes a combination of cytoreductive surgery, platinum-based chemotherapy, targeted therapies, and immunotherapy. Platinum-based chemotherapy drugs such as cisplatin, carboplatin, paclitaxel, and docetaxel are commonly used in combination therapy. Targeted therapies aim to selectively target molecules and mechanisms that cause chemoresistance, such as efflux pump inhibitors, tyrosine kinase inhibitors, and PARP inhibitors like olaparib. Immunotherapy, particularly immune checkpoint inhibitors, is being investigated in combination with chemotherapy, anti-angiogenetics, PARP inhibitors, and radiotherapy. The use of poly ADP-ribose polymerase (PARP) inhibitors, bevacizumab, and drugs targeting homologous recombination deficiency is becoming more common in the treatment of ovarian cancer. Overall, a comprehensive approach involving surgery, chemotherapy, targeted therapies, and immunotherapy is necessary for the effective treatment of ovarian cancer.
What's the relationship between ovarian cancer and diabetes?5 answersOvarian cancer has been found to have a relationship with diabetes mellitus (DM) according to the studies. A systematic review and meta-analysis of observational studies showed a weak but still significant association between DM and ovarian cancer risk. Another study found that ovarian cancer survivors had an increased risk of type II diabetes compared to the general population, particularly within the first year after cancer diagnosis. Additionally, a genetic screening study identified genes and proteins related to glycometabolism that could serve as potential targets in ovarian cancer treatment. Furthermore, a retrospective cohort study found that patients with diabetes had significantly shorter overall survival and progression-free survival rates compared to patients without diabetes. Overall, the studies suggest that there is a relationship between ovarian cancer and diabetes, with diabetes potentially impacting the risk, prognosis, and survival outcomes of ovarian cancer patients.
What are novel treatments for ovarian cancer?5 answersNovel treatments for ovarian cancer include the use of poly-ADP-ribose polymerase (PARP) inhibitors such as olaparib, rucaparib, and niraparib, which have been approved for use in ovarian cancer treatment and maintenance therapy. These drugs have shown effectiveness in targeting DNA repair pathways and have improved outcomes for patients with BRCA mutations as well as unselected patients. Additionally, bevacizumab, a vascular endothelial growth factor inhibitor, has been approved for extended use in ovarian cancer treatment, both as part of initial therapy and as an option for maintenance therapy. Immunotherapy is also being explored as a potential treatment option, either alone or in combination with chemotherapy, bevacizumab, or PARP inhibitors. Other promising approaches include targeting the p53 mutation, inhibiting tumor cell apoptosis, and the development of new chemotherapy compounds.